Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

#3776

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Aim(s): Retrospective analysis of the outcome and adverse effects of PRRT in patients treated with PRRT ([90Y]Y-DOTA-TATE or [90Y]Y/[177Lu]Lu-DOTA-TATE) as a first line treatment due to metastatic GEP-NET.

Materials and methods: Thirteen patients (7 men and 6 women) treated with PRRT as a first line treatment due to metastatic GEP-NET in 2007-2013 were eligible to analysis. Median age was 57,5 years (range 32-73). There were 6 patients with pancreatic, 5 with small intestine, 2 with large intestine NET and 1 subject with unknown primary site (8 cases of NET G2, 1 NET G1 and 5 without grade assessed). Eleven patients had removed the primary site. All patients had liver, 9 lymph node, and 5 bone metastases.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,